Teewinot Capital Advisers L.L.C. lowered its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 1.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 87,058 shares of the company’s stock after selling 1,048 shares during the period. Eli Lilly and Company makes up approximately 7.8% of Teewinot Capital Advisers L.L.C.’s portfolio, making the stock its 5th largest position. Teewinot Capital Advisers L.L.C.’s holdings in Eli Lilly and Company were worth $78,821,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Core Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the last quarter. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company in the second quarter valued at about $32,000. LGT Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $36,000. Frank Rimerman Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth $37,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth about $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.
Insiders Place Their Bets
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 8,848 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total value of $8,098,662.88. Following the completion of the transaction, the insider now directly owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 364,810 shares of company stock valued at $339,366,198. 0.13% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Price Performance
NYSE LLY opened at $877.79 on Monday. The stock’s 50-day moving average is $896.10 and its two-hundred day moving average is $844.12. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The firm has a market cap of $834.26 billion, a P/E ratio of 129.28, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- About the Markup Calculator
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.